Contact this trialFirst, we need to learn more about you.
Somatostatin Analog
Octreotide Depot for Neuroendocrine Tumors
Recruiting2 awardsPhase 3
Bronx, New York
This trial will compare the effectiveness and safety of a new drug (CAM2029) to existing treatments (octreotide LAR or lanreotide ATG) in patients with advanced, well-differentiated GEP-NET. If the new drug is not effective, patients may receive intensified treatment in the open-label extension part of the study.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.